A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer

Trial Profile

A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Crenigacestat (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 02 Jun 2017 Results(n=22) assessing tumor response presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 10 Apr 2017 Protocol has been amended to change in the treatment arm from 2 to 4 and change in patient number.
    • 04 Apr 2017 Planned number of patients changed from 227 to 282.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top